BofA lowered the firm’s price target on 89bio (ETNB) to $29 from $30 and keeps a Buy rating on the shares. 89bio’s Q2 report was “highlighted by execution” with key readouts of FGF21 pegozafermin in MASH and SHTG still on track, says the analyst, who cites updated operating expense forecasts for the price target change.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: